ERBB2 and neoplasm: HER2-targeting siRNAs either alone or fused to different aptamers have also been employed with encouraging results in mice models of breast and gastric cancers or in combination with classical chemotherapeutics to increase tumour responsiveness to treatment, especially in conditions of acquired drug resistance [11, 13, 14].